GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » ROE % Adjusted to Book Value
Switch to:

Biogen (BUE:BIIB) ROE % Adjusted to Book Value

: 26.80% (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Biogen's ROE % for the quarter that ended in Mar. 2023 was 12.33%. Biogen's PB Ratio for the quarter that ended in Mar. 2023 was 0.46. Biogen's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2023 was 26.80%.


Biogen ROE % Adjusted to Book Value Historical Data

The historical data trend for Biogen's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 83.04 31.88 66.37

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROE % Adjusted to Book Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.76 94.24 75.71 39.91 26.80

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen ROE % Adjusted to Book Value Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Biogen's ROE % Adjusted to Book Value falls in comparison to its industry or sector. The grey bar indicates the ROE % Adjusted to Book Value's extreme value range as defined by GuruFocus.



Biogen ROE % Adjusted to Book Value Calculation

Biogen's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=30.53% / 0.46
=66.37%

Biogen's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=12.33% / 0.46
=26.80%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Biogen's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines